Latest Content

Neoadjuvant Tyvyt With Chemo Improve Responses in Resectable, Locally Advanced ESCC

February 4th 2025, 8:00pm

By Chris Ryan

Article

In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an improvement in response rates.

When Cancer Makes You Cry, Cry It Out

February 4th 2025, 6:00pm

By Felicia Mitchell

Article

Even stoics need to cry now and then. My advice from personal experience is this: it is okay to cry.

World Cancer Day Shines Light on Therapeutic Advancements in Cancer Care

February 4th 2025, 4:00pm

By Ryan Scott

Article

Dr. John Oertle discussed the significance of World Cancer Day, raising awareness about cancer care advancements and improving patient outcomes.

Weight Gain Measurements May Be Underreported in ALK+ NSCLC Trials

February 4th 2025, 2:00pm

By Spencer Feldman

Article

Alecensa weight gain is underreported in ALK+ NSCLC trials, highlighting the need for increased awareness and proactive management of this side effect.

Tevimbra Plus Chemo May Be Safe, Effective in Advanced Gastric/GEJ Cancer

February 3rd 2025, 10:00pm

By Caroline Seymour

Article

Frontline treatment with Tevimbra plus irinotecan, paclitaxel, oxaliplatin and 5-FU/leucovorin had promising efficacy and manageable safety in gastric/GEJ cancer.

Rybrevant Alone and in Combo With Chemo is Efficacious in Wildtype+ mCRC

February 3rd 2025, 8:00pm

By Ryan Scott

Article

Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.

Breast Cancer Sucks But Sometimes Thoughtfulness Can Make It Better

February 3rd 2025, 6:00pm

By Bonnie Annis

Article

Breast cancer affected my looks and self-esteem, but I found small things could make a big difference in feeling pretty again.

Breaking Down Cancer Therapies Approved by the FDA in January 2025

February 3rd 2025, 4:00pm

By Ryan Scott

Article

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations like AML, MDS and breast cancer.

Cabometyx Demonstrates PFS Benefit Versus Placebo in GI-NETs

February 3rd 2025, 2:00pm

By Ryan Scott

Video

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced gastrointestinal NETs.

ITM-11 Meets Phase 3 Trial Primary End Point of PFS in GEP-NETs

February 2nd 2025, 7:00pm

By Ryan Scott

Article

Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive grade 1 or grade 2 GEP-NETs.

The Tap on the Shoulder: Cancer's Unexpected Call

February 1st 2025, 7:00pm

By France Di Vitto

Article

After a second breast cancer diagnosis at 61, I faced 17 rounds of chemo, surgery and radiation, changing my perspective on life and leading to a new normal.

Tevimbra Plus Chemotherapy May Improve Survival in First-Line ESCC

February 1st 2025, 3:00pm

By Courtney Flaherty

Article

Early and late responders with esophageal squamous cell carcinoma experienced comparable OS benefits with Tevimbra plus chemo in the RATIONALE-306 trial.

New Trial to Test Light Therapy Plus Keytruda in Head and Neck Cancer

January 31st 2025, 10:00pm

By Spencer Feldman

Article

A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck squamous cell carcinoma.

Breaking Down the Safety of BCG in Patients With NMIBC

January 31st 2025, 8:00pm

By Ryan Scott

Article

BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with chemo, fewer were reported.

Why Hope is Important For Patients with Chronic Lymphocytic Leukemia

January 31st 2025, 6:00pm

By Chester Freeman

Article

Hope is crucial for those of us with chronic lymphocytic leukemia, or any cancer, helping us navigate the disease's challenges.